Abstract
More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/ oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such receptor complex. Although there is still no clear explanation for the receptor dimerization/oligomerization, a large number of multivalent ligands (MLs) have been designed to target the receptor-dimers/oligomers. Such MLs have gained much acceptance in exploring the receptor complex of dopaminergic, adrenergic, serotoninergic, and opioidic receptor systems, due to the relatively broader experience in recognizing the receptor-dimerization. More and more MLs have also been designed to face GPCRrelated very complex neurodegenerative diseases, such as Parkinsons disease (PD), Alzheimers disease (AD) and schizophrenia, which are not effectively treated by traditional highly selective drugs. Herein, some of the most recent developments in this field, as well as some typical examples of MLs, are highlighted, with a particular focus on GPCRs.
Keywords: Multivalent ligand, G-protein-coupled receptors (GPCRs), drug design and development, heterodimerization, Parkinson's disease, Alzheimer's disease, schizophrenia, drug abuse, drug target
Current Pharmaceutical Design
Title: Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors
Volume: 15 Issue: 6
Author(s): Zhili Liu, Jing Zhang and Ao Zhang
Affiliation:
Keywords: Multivalent ligand, G-protein-coupled receptors (GPCRs), drug design and development, heterodimerization, Parkinson's disease, Alzheimer's disease, schizophrenia, drug abuse, drug target
Abstract: More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/ oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such receptor complex. Although there is still no clear explanation for the receptor dimerization/oligomerization, a large number of multivalent ligands (MLs) have been designed to target the receptor-dimers/oligomers. Such MLs have gained much acceptance in exploring the receptor complex of dopaminergic, adrenergic, serotoninergic, and opioidic receptor systems, due to the relatively broader experience in recognizing the receptor-dimerization. More and more MLs have also been designed to face GPCRrelated very complex neurodegenerative diseases, such as Parkinsons disease (PD), Alzheimers disease (AD) and schizophrenia, which are not effectively treated by traditional highly selective drugs. Herein, some of the most recent developments in this field, as well as some typical examples of MLs, are highlighted, with a particular focus on GPCRs.
Export Options
About this article
Cite this article as:
Liu Zhili, Zhang Jing and Zhang Ao, Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors, Current Pharmaceutical Design 2009; 15 (6) . https://dx.doi.org/10.2174/138161209787315639
DOI https://dx.doi.org/10.2174/138161209787315639 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
5-ht6 Receptors
Current Drug Targets - CNS & Neurological Disorders Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring
Current HIV Research Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Current Pharmaceutical Design New Assay for Old Markers-Plasma Beta Amyloid of Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Analytical Methodologies for Chloramphenicol Residues Determination in Food Matrixes: A Brief Review
Current Pharmaceutical Analysis Meet Our Regional Editor
Current Bioactive Compounds Host Background Factors Contributing to Hepatitis C Virus Clearance
Current Pharmaceutical Biotechnology Conformational Changes Preceding Amyloid-Fibril Formation of Amyloid- Beta, Prion Protein and Stefin B; Parallels in pH Dependence
Medicinal Chemistry Reviews - Online (Discontinued) The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Current Neuropharmacology Discovering New In Silico Tools for Antimicrobial Peptide Prediction
Current Drug Targets Vascular Lesion Thickness in the Lenticulostriate Artery Region Serves as a Biomarker for Early Neurological Deterioration
Current Neurovascular Research Homochiral Drug Design and Development by Racemization
Combinatorial Chemistry & High Throughput Screening Regulation of Gene Expression in Vascular Cells by Coagulation Proteins
Current Drug Targets Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa
CNS & Neurological Disorders - Drug Targets Pharmacological Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Ionic Liquids: A New Strategy in Pharmaceutical Synthesis
Mini-Reviews in Organic Chemistry Soft Computing Techniques for the Protein Folding Problem on High Performance Computing Architectures
Current Drug Targets Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review
Current Drug Abuse Reviews Role of Class II Nuclear Receptors in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry